Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545600 | 0.87 | RAB9A (0.57) | SMYD3HRH4HRH3NPC1RAB9A | |
| SCHEMBL605507 | 0.86 | HRH4 (0.58) | HRH4HRH3 | |
| SCHEMBL13175655 | 0.76 | AKR1C3 (0.65) | SMYD3KMT2AAKR1C3 | |
| SCHEMBL17938665 | 0.73 | NPC1 (0.78) | HRH4HRH3KMT2ANPC1RAB9A | |
| SCHEMBL1242690 | 0.71 | SMYD3 (0.53) | SMYD3 | |
| SCHEMBL19265216 | 0.71 | SMYD3 (0.51) | SMYD3KMT2ANPC1RAB9APOLB | |
| SCHEMBL29699763 | 0.71 | HRH4 (1.00) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL2679610 | 0.71 | HRH4 (1.00) | HRH4HRH3POLBSMN1; SMN2AKR1C3 | |
| SCHEMBL604553 | 0.70 | HRH4 (0.74) | HRH4HRH3NPC1RAB9ARHEB | |
| SCHEMBL20886821 | 0.69 | HRH4 (0.60) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185131-A1 | Heterocyclic Compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-08-09 | — | — | US | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2201982-A1 | Histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-7645758-B2 | Heterocyclic compounds | Janssen Pharmaceutica, N.Y. (BE) | 2010-01-12 | — | — | US | disclosed |
| EP-2010177-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120690-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| US-20070185131-A1 | Heterocyclic Compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-08-09 | — | — | US | disclosed |
| US-20070185120-A1 | Heterocyclic Compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-08-09 | — | — | US | disclosed |
| US-7226938-B2 | Heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-06-05 | — | — | US | disclosed |
| EP-1543011-B1 | THIENOPYRROLYL AND FURANOPYRROLYL COMPOUNDS AND THEIR USE AS HISTAMINE H4 RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20040048878-A1 | Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048878-A1 | Cyclopentathienopyrroles and cyclopentafuranopyrroles for treating disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis. | HRH4, HRH2, HRH1 | SMYD3 1750/4885HRH4 1/4885HRH3 4/4885 |
| US-20070185131-A1 | Heterocyclic Compounds | HRH4, HRH2, HRH1 | SMYD3 2276/4885HRH4 1/4885HRH3 4/4885 |
| US-20070185120-A1 | Heterocyclic Compounds | HRH4, HRH2, HRH1 | SMYD3 2276/4885HRH4 1/4885HRH3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.